Gemini Therapeutics
Developer of precision therapeutics for dry AMD and rare genetic diseases. The company's approach to drug discovery is genome-driven and multi-modal, i.e., therapeutics are targeted to specific genetic mutations, and are not limited to a single approach, and are tailored to the target. Founded in 2015, headquartered in Cambridge, United States. The company has raised $44.5M in funding at the series a stage. The team…
Funding snapshot
About
Developer of precision therapeutics for dry AMD and rare genetic diseases. The company's approach to drug discovery is genome-driven and multi-modal, i.e., therapeutics are targeted to specific genetic mutations, and are not limited to a single approach, and are tailored to the target. Founded in 2015, headquartered in Cambridge, United States. The company has raised $44.5M in funding at the series a stage. The team comprises 45 (Dec 31, 2022) employees. Gemini Therapeutics operates in the Rare Diseases, Genomics sectors. The company focuses on Metabolic Disorders, Therapeutics. Notable investors include Atlas Venture, Lightstone Ventures, Orbimed, Foresite Capital. The company has a team of 45 employees.
Business model
Rare Diseases > Drugs > Metabolic Disorders,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Team background
College Wise > University of Edinburgh
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.